24/7 Market News – (NASDAQ:RGLS) REGULUS THERAPEUTICS INC. Just announced the FDA orphan drug designation from the FDA.

June 21, 2022

Shares are up slightly in pre-market on light trading. currently .30 on only 498 trades.

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-receipt-of-fda-orphan-drug-designation-for-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-301571856.html

Pages: 1 2

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.